,Kathleen M. Giacomini,Shiew-Mei Huang,Donald J. Tweedie,Leslie Z. Benet,Kim L.R. Brouwer,Xiaoyan Chu,Amber Dahlin,Raymond Evers,Volker Fischer,Kathleen M. Hillgren,Keith A. Hoffmaster,Toshihisa Ishikawa,Dietrich Keppler,Richard B. Kim,Caroline A. Lee,Mikko Niemi,Joseph W. Polli,Yuicchi Sugiyama,Peter W. Swaan,Joseph A. Ware,Stephen H. Wright,Sook Wah Yee,Maciej J. Zamek-Gliszczynski,Lei Zhang

Abstract:Key PointsMembrane transporters are increasingly being recognized as important determinants of pharmacokinetics and have been found to play a role in the absorption and disposition of many drugs.In this report, the findings of the International Transporter Consortium (ITC), a group of individuals from academia, industry and regulatory agencies with expertise in membrane transporters, are presented. The goals of the ITC were to identify key transporters with a role in drug absorption and disposition; evaluate methodologies for characterization of drug transporter interactions; and develop criteria to inform the conduct of clinical drug–drug interaction (DDI) studies focused on transporters, which could be presented in the form of decision trees.The key transporters, P-glycoprotein (P-gp, ABCB1); breast cancer resistance protein (BCRP); organic anion transporters (OAT1 and OAT3); organic cation transporter (OCT2); and organic anion transporting polypeptides (OATP1B1 and OATP1B3), described in this report were selected based on evidence in the literature demonstrating that the transporters play a role in governing drug absorption and disposition and in mediating clinical DDIs.For each of the key transporters, substrate and inhibitors and methodologies for evaluating its function are described. The clinical significance of each transporter is discussed.An overview of the methods for studying drug interactions with transporters is presented including cell- and membrane-based systems, intact organs and in vivo models.A section on computational modelling algorithms using information from crystal structures and ligands is included to inform readers about the use of in silico methods to gain information about transporter–substrate interactions.A detailed discussion and suggested decision trees related to studying membrane transporters in drug development are described. The focus of the decision trees is on informing clinical DDI studies.

Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development

Scientific and Regulatory Perspectives on Metabolizing Enzyme−Transporter Interplay and Its Role in Drug Interactions: Challenges in Predicting Drug Interactions

Innovative Approaches to Optimize Clinical Transporter Drug-Drug Interaction Studies

Research progress in toxic effects of antitumor drugs based on drug transporter

Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier

Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine

Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug–Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective

Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions

A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators

Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

Membrane transporters in drug development

Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery

Transporter modulation by Chinese herbal medicines and its mediated pharmacokinetic herb-drug interactions

Prediction of Cytochrome 450 Mediated Drug-Drug Interactions by Three-Dimensional Cultured Hepatocytes

Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking

A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment

Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance